Pursuit Wealth Management LLC Purchases New Position in Hologic, Inc. $HOLX

Pursuit Wealth Management LLC acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 9,206 shares of the medical equipment provider’s stock, valued at approximately $686,000.

Other hedge funds have also bought and sold shares of the company. Becker Capital Management Inc. lifted its holdings in Hologic by 20.0% during the 3rd quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after purchasing an additional 13,610 shares in the last quarter. Natixis Advisors LLC grew its holdings in Hologic by 23.4% during the 3rd quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after buying an additional 82,894 shares in the last quarter. Illinois Municipal Retirement Fund increased its position in shares of Hologic by 20.4% during the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after buying an additional 29,143 shares during the period. Readystate Asset Management LP purchased a new stake in shares of Hologic in the third quarter worth about $4,161,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Hologic by 5.0% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 451,581 shares of the medical equipment provider’s stock worth $30,477,000 after buying an additional 21,369 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $76.01 on Thursday. The stock’s 50-day moving average is $75.45 and its 200 day moving average is $74.17. The stock has a market cap of $16.97 billion, a price-to-earnings ratio of 31.67, a P/E/G ratio of 2.24 and a beta of 0.70. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $76.07. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.87 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HOLX shares. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.